Profile data is unavailable for this security.
About the company
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
- Revenue in SEK (TTM)0.00
- Net income in SEK-241.07m
- Incorporated2009
- Employees23.00
- LocationCantargia ABScheelevagen 27LUND 223 63SwedenSWE
- Phone+46 462756260
- Websitehttps://cantargia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Saniona AB | 20.71m | -83.30m | 408.24m | 23.00 | -- | 14.98 | -- | 19.71 | -1.09 | -1.09 | 0.2629 | 0.2451 | 0.1726 | -- | 5.63 | 900,521.80 | -69.41 | -59.16 | -127.89 | -70.15 | -136.88 | -970.05 | -402.20 | -1,483.55 | -- | -3.85 | 0.71 | -- | 10.19 | -21.05 | 54.71 | -- | -34.94 | -- |
Xbrane Biopharma AB | 190.97m | -361.27m | 412.96m | 75.00 | -- | 1.05 | -- | 2.16 | -1.33 | -1.58 | 0.6978 | 0.2577 | 0.2465 | 1.34 | 332.12 | 2,053,430.00 | -46.63 | -40.98 | -78.01 | -67.24 | 15.43 | -- | -189.18 | -364.40 | 1.43 | -31.13 | 0.3693 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
Mendus AB (publ) | 0.00 | -107.06m | 417.98m | 28.00 | -- | 0.5329 | -- | -- | -1.59 | -1.59 | 0.00 | 15.57 | 0.00 | -- | -- | 0.00 | -16.09 | -18.84 | -17.35 | -20.21 | -- | -- | -- | -28,474.53 | -- | -150.86 | 0.0348 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
Lytix Biopharma AS | 3.96m | -87.20m | 441.98m | 10.00 | -- | 7.12 | -- | 111.63 | -2.16 | -2.16 | 0.0981 | 1.26 | 0.0368 | -- | 0.4091 | 399,100.00 | -80.96 | -56.91 | -94.07 | -65.83 | -- | -- | -2,202.36 | -771.78 | -- | -- | 0.0095 | -- | -63.82 | 63.94 | -56.77 | -- | -- | -- |
Bergenbio ASA | 516.88k | -153.30m | 444.40m | 16.00 | -- | 330.18 | -- | 859.77 | -0.1849 | -0.1849 | 0.0003 | 0.0347 | 0.0047 | -- | 0.0485 | 20,840.00 | -139.81 | -66.15 | -275.19 | -78.74 | -- | -- | -29,658.54 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
Hamlet BioPharma AB | 0.00 | -33.41m | 472.73m | 7.00 | -- | 8.17 | -- | -- | -0.2326 | -0.2326 | 0.00 | 0.453 | 0.00 | -- | -- | -- | -63.45 | -83.52 | -69.09 | -107.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
Initiator Pharma A/S | 0.00 | -34.30m | 499.28m | 3.00 | -- | 14.67 | -- | -- | -0.6301 | -0.6301 | 0.00 | 0.643 | 0.00 | -- | -- | 0.00 | -70.60 | -68.27 | -73.77 | -74.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
Oncopeptides AB | 39.17m | -245.79m | 534.95m | 62.00 | -- | -- | -- | 13.66 | -1.93 | -1.93 | 0.3085 | -0.0664 | 0.1517 | -0.2669 | 0.8075 | 687,157.90 | -95.16 | -141.28 | -135.11 | -200.49 | 102.05 | -- | -627.53 | -2,689.06 | 2.33 | -- | 1.06 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
Intellego Technologies AB | 223.23m | 81.38m | 706.25m | 62.00 | 8.72 | 3.63 | 8.22 | 3.16 | 3.07 | 3.07 | 8.53 | 7.39 | 0.9087 | 5.24 | 2.82 | 3,600,549.00 | 33.13 | -- | 46.94 | -- | 68.45 | -- | 36.46 | -- | 2.13 | 7.89 | 0.1833 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
Promimic AB | 39.53m | -9.38m | 744.43m | 17.00 | -- | 10.20 | -- | 18.83 | -0.5067 | -0.5067 | 2.14 | 3.91 | 0.4533 | -4.61 | 5.46 | 2,325,471.00 | -10.75 | -24.89 | -12.43 | -29.25 | 104.25 | 101.23 | -23.73 | -89.47 | 4.13 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
Cantargia AB | 0.00 | -241.07m | 779.93m | 23.00 | -- | 5.87 | -- | -- | -1.40 | -1.40 | 0.00 | 0.7239 | 0.00 | -- | -- | 0.00 | -83.14 | -55.08 | -107.52 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
Alligator Bioscience AB | 55.49m | -248.80m | 818.68m | 55.00 | -- | -- | -- | 14.75 | -0.4848 | -0.4848 | 0.0999 | -0.0772 | 0.5289 | -- | 8.07 | 956,741.40 | -237.13 | -73.26 | -- | -91.33 | -- | -- | -448.35 | -811.68 | -- | -104.20 | -- | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
Data as of Jul 05 2024. Currency figures normalised to Cantargia AB's reporting currency: Swedish Krona SEK
Holder | Shares | % Held |
---|---|---|
Fj�rde AP-fondenas of 31 Dec 2023 | 18.12m | 9.87% |
F�rsta AP-fondenas of 31 Dec 2023 | 13.00m | 7.08% |
Alecta Pension Insurance Mutualas of 30 Jun 2023 | 10.10m | 5.50% |
Handelsbanken Fonder ABas of 30 Jun 2024 | 5.84m | 3.18% |
Swedbank Robur Fonder ABas of 31 May 2024 | 3.69m | 2.01% |
SEB Investment Management ABas of 31 May 2024 | 1.01m | 0.55% |
FCG Fonder ABas of 31 Dec 2023 | 473.80k | 0.26% |
SSgA Funds Management, Inc.as of 06 Jun 2024 | 354.56k | 0.19% |
Alfred Berg Kapitalforvaltning ASas of 30 Jun 2023 | 160.18k | 0.09% |
Skandia Investment Management ABas of 31 May 2024 | 113.71k | 0.06% |
More ▼
Data from 29 Mar 2024 - 31 May 2024Source: FactSet Research Systems Inc.